Abstract
This commentary explores the recent experience with and the basis for the use of selective estrogen receptor modulators (SERMs) to prevent breast cancer. Chcmoprevention has been a goal for many years. As newer agents arc unveiled, they will continue to be tested against tamoxifen, the current standard for the treatment and prevention of breast cancer. Raloxifene holds the promise of treating osteoporosis with the beneficial side effect of breast cancer prevention. The Study of Tamoxifen and Raloxifene (STAR) trial and prior prevention studies will be discussed in an attempt understand the bridge from the laboratory to the clinic.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 401-407 |
| Number of pages | 7 |
| Journal | Oncology Research |
| Volume | 11 |
| Issue number | 9 |
| State | Published - 1999 |
Keywords
- Antiestrogens
- Breast cancer
- Raloxifene
- Tamoxifen
ASJC Scopus subject areas
- Oncology
- Cancer Research
